Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior immunity, we evaluate...

Full description

Bibliographic Details
Main Authors: Laurence Peiperl, Cecilia Morgan, Zoe Moodie, Hongli Li, Nina Russell, Barney S Graham, Georgia D Tomaras, Stephen C De Rosa, M Juliana McElrath, NIAID HIV Vaccine Trials Network
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-10-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2965084?pdf=render

Internet

http://europepmc.org/articles/PMC2965084?pdf=render

Similar Items